expands and enters pipe Immunology stem cell en campo a través
Trillium Therapeutics Inc. (TTI) a biopharmaceutical company developing innovative biological immune system, has announced that it has signed two definitive licensing agreements with University Health Network (UHN) and the Hospital for Sick Children (SickKids) in Toronto, Ontario, the Trillium grant worldwide exclusive rights to commercialize two programs in the areas of immunology transplantation hematopoietic stem cells and cancer.
"We are very pleased to have strengthened our franchise in immunology and have strengthened our existing ties with the world of Toronto community of immunology class. Our relationship with long-term productive UHN is a good omen for the success of this new collaboration, "said Dr. Niclas Stiernholm, CEO of Trillium. "This transaction is an example of how Canadian soil science deals can and should be marketed by our national biotechnology industry, something that should be encouraged and supported also by the government and investor groups.
The first project approved by TTI is to improve the engraftment of hematopoietic stem cells by way of a key immunoregulatory anxious to evade the host immune system from attacking the transplanted stem cells. The second program focuses on the treatment of various cancers by way of antagonizing the same cancer stem cells, stimulating the patient's own immune system to attack cancer. Drs. John Dick, and Jean Wang of UHN, and Dr. Jayne Danish, world renowned scientists in their respective fields and the inventors of these technologies, first published its initial findings in the journal Nature Immunology in December 2007. Through co-sponsored research agreements, which will work closely with Trillium scientific team to advance this cutting-edge science of human testing.
Dr. Christopher Paige, VP Research at UHN said: "We are very pleased to have established this partnership with a dynamic company like Canadian biotechnology Trillium Therapeutics. Represents an excellent example of how research in hospitals and SickKids can work UHN together to translate cutting-edge discoveries research on new product development opportunities. "Dr. Janet Rossant, SickKids Chief of Research added" research collaborations between scientists of our institutions have now been extended to interactions with the private sector development, which clearly indicates that we can provide research and biotherapeutic development together in Toronto. "
Related article
cord
Bank
cord stem cell bank
umbilical cord stem cells
Friday, March 19, 2010
Fur Lined Toilet Seat
función de las células madre Caracterizado por los investigadores
The promise of cells mother lies in its unique ability to differentiate into a variety of different cell types. But in order to determine how to use stem cells for new therapies, scientists and engineers who need to answer a fundamental question: if a stem cell changes to look like a certain type of cell, how do we know if it behaves as a kind Cell?
Researchers at Northwestern University's McCormick School of Engineering are the first to fully characterize a special type of stem cells, endothelial progenitor cells (EPC) that exist in blood circulation, to see if they behave as endothelial cells in the body when grown in the bioengineering area.
The results, published online in the journal Stem Cells promising a new generation of tissue engineered vascular grafts, which could improve the success rate of surgery for peripheral arterial disease. Peripheral artery disease affects an estimated one in 20 Americans over age 50, a total of 8 to 12 million people.
"Normally, stem cells are not studied in the context of improved vascular grafts for bypass surgery. Therefore, we had to develop new tests to assess Its use in this application, "says Guillermo Ameer, lead author and associate professor of biomedical engineering and surgery." We looked at the role of cells in a polymer-based citric acid, which is the basis for new generation of bioengineered vascular grafts. "
In the study, Josephine Allen, then a graduate student in the lab of Amir and his colleagues isolated endothelial progenitor cells from eight tablespoons of blood. In about half the attempts, the team was able to isolate the CPE to expand the production of millions of endothelial cells may behave like the cells of a blood vessel.
Once the endothelium, and cell colonies were established, the research team performed a battery of tests to examine the properties and functionality of the cell.
"These new tests show that these endothelial cells, and can inhibit blood clotting and can prevent platelets from adhering to its surface," says Amir. "But if antagonize or stimulate cells, but also respond in the same way that one of the endothelial cells and blood clot if necessary."
The study is an important step in identifying methods to construct a tissue engineered vascular graft. Synthetic grafts, used to treat common diseases such as peripheral arterial disease, have lower success rates when used in small diameter arteries, such as those found in the leg.
"These small diameter synthetic grafts are more prone to blood clots and other complications, especially in the time," says Amir. "It is believed that a graft of tissue engineering that allow us to retain more of the body's natural defenses against the complications."
The document is entitled Stem Cell "Towards Engineering a human Neoendothelium circulating progenitor cells." Amir addition, other authors are Josephine B. Allen, Sadiya Khan and Karen A. Lapidos, all from Northwestern.
The work was funded by the Institute of Regenerative Medicine in Illinois, the Department of Defense and the American Heart Association. Related article
cord
Bank
cord stem cell bank
umbilical cord stem cells
The promise of cells mother lies in its unique ability to differentiate into a variety of different cell types. But in order to determine how to use stem cells for new therapies, scientists and engineers who need to answer a fundamental question: if a stem cell changes to look like a certain type of cell, how do we know if it behaves as a kind Cell?
Researchers at Northwestern University's McCormick School of Engineering are the first to fully characterize a special type of stem cells, endothelial progenitor cells (EPC) that exist in blood circulation, to see if they behave as endothelial cells in the body when grown in the bioengineering area.
The results, published online in the journal Stem Cells promising a new generation of tissue engineered vascular grafts, which could improve the success rate of surgery for peripheral arterial disease. Peripheral artery disease affects an estimated one in 20 Americans over age 50, a total of 8 to 12 million people.
"Normally, stem cells are not studied in the context of improved vascular grafts for bypass surgery. Therefore, we had to develop new tests to assess Its use in this application, "says Guillermo Ameer, lead author and associate professor of biomedical engineering and surgery." We looked at the role of cells in a polymer-based citric acid, which is the basis for new generation of bioengineered vascular grafts. "
In the study, Josephine Allen, then a graduate student in the lab of Amir and his colleagues isolated endothelial progenitor cells from eight tablespoons of blood. In about half the attempts, the team was able to isolate the CPE to expand the production of millions of endothelial cells may behave like the cells of a blood vessel.
Once the endothelium, and cell colonies were established, the research team performed a battery of tests to examine the properties and functionality of the cell.
"These new tests show that these endothelial cells, and can inhibit blood clotting and can prevent platelets from adhering to its surface," says Amir. "But if antagonize or stimulate cells, but also respond in the same way that one of the endothelial cells and blood clot if necessary."
The study is an important step in identifying methods to construct a tissue engineered vascular graft. Synthetic grafts, used to treat common diseases such as peripheral arterial disease, have lower success rates when used in small diameter arteries, such as those found in the leg.
"These small diameter synthetic grafts are more prone to blood clots and other complications, especially in the time," says Amir. "It is believed that a graft of tissue engineering that allow us to retain more of the body's natural defenses against the complications."
The document is entitled Stem Cell "Towards Engineering a human Neoendothelium circulating progenitor cells." Amir addition, other authors are Josephine B. Allen, Sadiya Khan and Karen A. Lapidos, all from Northwestern.
The work was funded by the Institute of Regenerative Medicine in Illinois, the Department of Defense and the American Heart Association. Related article
cord
Bank
cord stem cell bank
umbilical cord stem cells
Can You Get A Std On Belly And Back
Novela el tratamiento del ictus Pases de Seguridad de escena de la UCI-Led de ensayos clínicos
A clinical research study of a new treatment to restore damaged brain cells from stroke has passed a safety milestone, according to the neurologist at UC Irvine, who led the effort.
Dr. Steven C. Cramer said the patients showed no adverse effects after sequential administration of growth factors, stimulating the creation of neurons in stroke-damaged brain areas. All new security pharmaceutical treatments should pass this stage before doctors could study their effectiveness in future studies.
The results of a Phase IIa trial appear on the website of the journal Stroke, a journal of the American Association Heart.
Within two days of suffering an ischemic stroke, patients were placed in a nine-day course of treatment, starting with three injections once daily of beta-hCG, a hormone that causes the growth of stem cells neural . Then, once received three daily injections of erythropoietin, a hormone that directs neural stem cells to become neurons.
Cramer, associate professor of neurology at UCI, said this combination of growth factors has been demonstrated in animal studies to generate the creation of the neuron leading to the recovery range of motion.
The study of human security, teamed with doctors at the University of California Irvine Medical Center, Hoag Memorial Hospital Presbyterian in Newport Beach, California, and the University of Calgary in Canada. Treatment was administered to 15 patients. There were no security problems, and most patients with minimal or no disability after three months.
A Phase IIb trial currently underway to compare the movement therapy with placebo.
The study is supported by Stem Cell Therapeutics - a Canadian biotechnology company that devised an approach using the sequence specific growth factors - and the National Center for Research Resources. Related article
cord
Bank
cord stem cell bank
umbilical cord stem cells
A clinical research study of a new treatment to restore damaged brain cells from stroke has passed a safety milestone, according to the neurologist at UC Irvine, who led the effort.
Dr. Steven C. Cramer said the patients showed no adverse effects after sequential administration of growth factors, stimulating the creation of neurons in stroke-damaged brain areas. All new security pharmaceutical treatments should pass this stage before doctors could study their effectiveness in future studies.
The results of a Phase IIa trial appear on the website of the journal Stroke, a journal of the American Association Heart.
Within two days of suffering an ischemic stroke, patients were placed in a nine-day course of treatment, starting with three injections once daily of beta-hCG, a hormone that causes the growth of stem cells neural . Then, once received three daily injections of erythropoietin, a hormone that directs neural stem cells to become neurons.
Cramer, associate professor of neurology at UCI, said this combination of growth factors has been demonstrated in animal studies to generate the creation of the neuron leading to the recovery range of motion.
The study of human security, teamed with doctors at the University of California Irvine Medical Center, Hoag Memorial Hospital Presbyterian in Newport Beach, California, and the University of Calgary in Canada. Treatment was administered to 15 patients. There were no security problems, and most patients with minimal or no disability after three months.
A Phase IIb trial currently underway to compare the movement therapy with placebo.
The study is supported by Stem Cell Therapeutics - a Canadian biotechnology company that devised an approach using the sequence specific growth factors - and the National Center for Research Resources. Related article
cord
Bank
cord stem cell bank
umbilical cord stem cells
Subscribe to:
Posts (Atom)